J&J To Buy Intra-Cellular, Psychiatric Drug Caplyta For $14.6bn
Deal May Launch Anticipated Year Of Larger M&A
Johnson & Johnson started the M&A year with a bang at the J.P. Morgan meeting, unveiling its $14.6bn bid for Intra-Cellular. The deal would bolster its neuroscience portfolio and pipeline.
